A Multicenter, Rand., Double-Blind, Parallel-Group, Pbo-Controlled Study of the Efficacy and Safety of SEROQUEL XR [quetiapine] Compared With Pbo as an Adjunct to Treatment in Patients With Generalized Anxiety Disorder Who Demonstrate Partial or No Response to a SSRI or SNRI Alone or in Combination With a Benzo.

Trial Profile

A Multicenter, Rand., Double-Blind, Parallel-Group, Pbo-Controlled Study of the Efficacy and Safety of SEROQUEL XR [quetiapine] Compared With Pbo as an Adjunct to Treatment in Patients With Generalized Anxiety Disorder Who Demonstrate Partial or No Response to a SSRI or SNRI Alone or in Combination With a Benzo.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2011

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Jul 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 08 Jul 2009 Trial phase changed from II to III as reported by ClinicalTrials.gov.
    • 30 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top